412 related articles for article (PubMed ID: 15513361)
1. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma.
Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M
Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between anti-tumor effects and serum hepatocyte growth factor level in patients with liver metastases from gastric cancer treated by induced hypertensive chemotherapy with angiotensin II].
Iwasaki Y; Kitamura M; Arai K
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1874-7. PubMed ID: 9382555
[TBL] [Abstract][Full Text] [Related]
3. Elevation of serum hepatocyte growth factor concentration in patients with gastric cancer is mediated by production from tumor tissue.
Beppu K; Uchiyama A; Morisaki T; Nakamura K; Noshiro H; Matsumoto K; Nakamura T; Tanaka M; Katano M
Anticancer Res; 2000; 20(2B):1263-7. PubMed ID: 10810432
[TBL] [Abstract][Full Text] [Related]
4. The use of tumor markers as predictors of prognosis in gastric cancer.
Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
[TBL] [Abstract][Full Text] [Related]
5. [mRNA expression of basic fibroblast growth factor and hepatocyte growth factor in gastric carcinoma and significance thereof].
Ru GQ; Zhao ZS; Tang QL; Xu WJ
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2030-5. PubMed ID: 19080429
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
7. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma.
Guadagni F; Roselli M; Amato T; Cosimelli M; Perri P; Casale V; Carlini M; Santoro E; Cavaliere R; Greiner JW
Cancer Res; 1992 Mar; 52(5):1222-7. PubMed ID: 1737383
[TBL] [Abstract][Full Text] [Related]
8. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
9. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
[TBL] [Abstract][Full Text] [Related]
10. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer.
Toi M; Taniguchi T; Ueno T; Asano M; Funata N; Sekiguchi K; Iwanari H; Tominaga T
Clin Cancer Res; 1998 Mar; 4(3):659-64. PubMed ID: 9533534
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of hepatocyte growth factor in breast cancer patients.
Taniguchi T; Toi M; Inada K; Imazawa T; Yamamoto Y; Tominaga T
Clin Cancer Res; 1995 Sep; 1(9):1031-4. PubMed ID: 9816076
[TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: study on 166 cases and suggestion for new therapy.
Zhang YH; Li Y; Chen C; Peng CW
Hepatogastroenterology; 2009; 56(96):1750-4. PubMed ID: 20214231
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer.
Kodera Y; Yamamura Y; Torii A; Uesaka K; Hirai T; Yasui K; Morimoto T; Kato T; Kito T
Am J Gastroenterol; 1996 Jan; 91(1):49-53. PubMed ID: 8561143
[TBL] [Abstract][Full Text] [Related]
14. Serum hepatocyte growth factor level associate with gastric cancer progression.
Wu CW; Chi CW; Su TL; Liu TY; Lui WY; P'eng FK
Anticancer Res; 1998; 18(5B):3657-9. PubMed ID: 9854473
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of CA72-4 as a tumor marker in patients with gastric cancer].
Ubukata H; Katano M; Motohashi G; Kasuga T; Takemura A; Tabuchi T; Tabuchi T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1821-4. PubMed ID: 14619529
[TBL] [Abstract][Full Text] [Related]
16. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
17. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
[TBL] [Abstract][Full Text] [Related]
18. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
19. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
[TBL] [Abstract][Full Text] [Related]
20. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
Tsai WS; Changchien CR; Yeh CY; Chen JS; Tang R; Chiang JM; Hsieh PS; Fan CW; Wang JY
Dis Colon Rectum; 2006 Jun; 49(6):883-94. PubMed ID: 16741643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
